• Product NameAxitinib
• Brief DescriptionInhibitors
• Purification98.90%
• Biological ActivityAxitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. Axitinib is marketed under the name Inlyta?, and if one previous systemic therapy for kidney cell Y has failed, axitinib is indicated.
• Target NamePDGFR inhibitor; VEGFR inhibitor
• CAS No. 319460-85-0
• Calculated MW 386.47
• Formulation C22H18N4OS
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:CNC(=O)C1=CC=CC=C1SC2=CC3=C(C=C2)C(=NN3)/C=C/C4=CC=CC=N4
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:PDGFRβ; VEGFR1/FLT1; VEGFR2/Flk1; VEGFR2/KDR; VEGFR3
  Boling pt:668.9C
  Melting pt:213-215C
  Solubility:DMSO: 35 mg/mL warmed (90.56 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Hu-Lowe DD, et al. Clin Y Res, 2008, 14(22), 7272-7283.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting